De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

HPGC Renmintongtai Pharmaceutical Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Weidong Zhu

Algemeen directeur

CN¥1.2m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	9.6yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	2.6yrs
Gemiddelde ambtstermijn bestuur	1.5yrs

Recente managementupdates

Recent updates

CEO

Weidong Zhu (55 yo)

9.6yrs

Tenure

CN¥1,232,100

Compensatie

Mr. Weidong Zhu served as Deputy General Manager at HPGC Renmintongtai Pharmaceutical Corporation. Mr. Zhu serves as Deputy General Manager and General manager of Harbin Renmintongtai Pharmacy chain stores...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Weidong Zhu	GM & Chairman	no data	CN¥1.23m	geen gegevens
Ping Guan	Deputy GM & CFO	2.5yrs	CN¥645.00k	geen gegevens
Cong Feng Gu	Deputy GM & Director	no data	CN¥985.00k	geen gegevens
Lei Wang	Board Secretary	2.6yrs	CN¥217.20k	geen gegevens
Jin Zhang	Chief Accountant	9.6yrs	CN¥176.80k	geen gegevens

2.6yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 600829 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Weidong Zhu	GM & Chairman	9.6yrs	CN¥1.23m	geen gegevens
Cong Feng Gu	Deputy GM & Director	no data	CN¥985.00k	geen gegevens
Xiaodong Meng	Chairman of the Supervisory Board	2.3yrs	geen gegevens	geen gegevens
Bin Wu	Independent Director	5.3yrs	CN¥80.00k	geen gegevens
Peng Yuan Cheng	Director	less than a year	geen gegevens	geen gegevens
Dan Guo	Independent Director	less than a year	geen gegevens	geen gegevens
Shiwei Yin	Director	less than a year	geen gegevens	geen gegevens

1.5yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 600829 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.5 jaar), wat duidt op een nieuw bestuur.

HPGC Renmintongtai Pharmaceutical Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

HPGC Renmintongtai Pharmaceutical Corporation, Annual General Meeting, Jun 06, 2024

Less than half of directors are independent

Recent updates

Investor sentiment improves as stock rises 21%

HPGC Renmintongtai Pharmaceutical Corporation to Report Q3, 2024 Results on Oct 22, 2024

Investor sentiment improves as stock rises 22%

Second quarter 2024 earnings released: EPS: CN¥0.098 (vs CN¥0.14 in 2Q 2023)

HPGC Renmintongtai Pharmaceutical Corporation to Report First Half, 2024 Results on Aug 09, 2024

HPGC Renmintongtai Pharmaceutical Corporation, Annual General Meeting, Jun 06, 2024

New minor risk - Dividend sustainability

HPGC Renmintongtai Pharmaceutical Corporation to Report Q1, 2024 Results on Apr 20, 2024

Full year 2023 earnings released: EPS: CN¥0.50 (vs CN¥0.45 in FY 2022)

Investor sentiment deteriorates as stock falls 16%

HPGC Renmintongtai Pharmaceutical Corporation to Report Fiscal Year 2023 Results on Mar 28, 2024

Third quarter 2023 earnings released: EPS: CN¥0.15 (vs CN¥0.15 in 3Q 2022)

HPGC Renmintongtai Pharmaceutical Corporation to Report Q3, 2023 Results on Oct 25, 2023

New minor risk - Share price stability

Investor sentiment improves as stock rises 27%

Second quarter 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.10 in 2Q 2022)

HPGC Renmintongtai Pharmaceutical Corporation to Report First Half, 2023 Results on Aug 12, 2023

Full year 2022 earnings released: EPS: CN¥0.45 (vs CN¥0.48 in FY 2021)

Full year 2022 earnings released: EPS: CN¥0.44 (vs CN¥0.48 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.17 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.17 in 2Q 2021)

Full year 2021 earnings released: EPS: CN¥0.48 (vs CN¥0.25 in FY 2020)

Third quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.10 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.056 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.069 (vs CN¥0.083 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.25 (vs CN¥0.46 in FY 2019)

New 90-day low: CN¥5.79

HPGC Renmintongtai Pharmaceutical Corporation to Report Fiscal Year 2020 Results on Mar 20, 2021

Investor sentiment deteriorated over the past week

New 90-day low: CN¥6.62

New 90-day high: CN¥7.77

New 90-day low: CN¥7.10

Third quarter earnings released

HPGC Renmintongtai Pharmaceutical Corporation to Report Q3, 2020 Results on Oct 17, 2020

New 90-day low: CN¥7.28

Earnings released

New 90-day high - CN¥8.53

HPGC Renmintongtai Pharmaceutical Corporation to Report First Half, 2020 Results on Aug 15, 2020

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd